WebAug 3, 2024 · Small Pharma is a biotechnology company progressing a pipeline of short-acting psychedelics with therapy for the treatment of mental health conditions, with a current focus on depression. Small Pharma initiated a clinical program into DMT-assisted psychotherapy in February 2024. WebNov 30, 2024 · Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London. For further information contact: Small Pharma Inc. Peter Rands Chief Executive Officer Email: [email protected] Tel: +44 (0)2071 129118 Media Relations Contact
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
WebOct 14, 2024 · MHRA approval for new SPL026 trial. LONDON, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Small Pharma Inc. DMT. DMTTF. (the " Company " or " Small Pharma "), a biotechnology company focused on short-acting ... WebMay 31, 2024 · SMALL PHARMA INC. (FORMERLY, UNILOCK CAPITAL CORP.) Management's Discussion and Analysis of Financial Condition and Results of Operations For the three months ended May 31, 2024 Date: July 14, 2024 SMALL PHARMA INC. Management's Discussion and Analysis define panic of 1819
Small Pharma Successfully Completes Phase I Clinical Trial Of …
WebSep 17, 2024 · ESSA Pharma Inc. ("ESSA", or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial support agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen") to enable evaluation … WebJun 9, 2024 · Small Pharma is advancing a pipeline of DMT-based therapies and is leading the most advanced clinical trial in commercial development for DMT-assisted psychotherapy in MDD. For further information contact: Small Pharma Inc. Peter Rands Chief Executive Officer Email: [email protected] Tel: +44 (0)20 7112 9118 WebOct 14, 2024 · Small Pharma is a biotechnology company progressing a pipeline of short-acting psychedelic assisted therapies for the treatment of mental health conditions. The Company’s current focus is on exploring new therapeutic approaches for depression. Small Pharma’s lead candidate, SPL026, is a proprietary synthetic formulation of DMT. feenix rinne lounas